TMDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TransMedics Group Inc (TMDX) is not a strong buy at the moment for a beginner, long-term investor. While the company has shown impressive financial growth and positive analyst sentiment, the technical indicators suggest a bearish trend with oversold conditions, and insider selling activity raises concerns. Additionally, there are no strong trading signals or recent positive news catalysts to support an immediate buy decision.
The stock is currently in a bearish trend with a negatively expanding MACD histogram (-2.528) and an RSI of 11.508, indicating oversold conditions. The pre-market price is $101.5, down -0.68%, and the stock is trading near its S1 support level of 104.681, with S2 at 98.452. Moving averages are converging, signaling potential indecision in the market.
Strong financial performance in Q4 2025, with revenue up 32.18% YoY and net income up 1436.87% YoY. EPS also increased significantly by 1252.63% YoY.
Analysts have raised price targets significantly, with many maintaining Buy or Outperform ratings.
The company is investing in clinical trials and expanding its market presence, particularly in Europe.
Insider selling has increased by 186.38% over the last month, which could indicate a lack of confidence from internal stakeholders.
The MACD and RSI suggest a bearish trend, and the stock is trading below key pivot levels.
No recent news or event-driven catalysts to drive immediate upward momentum.
Hedge funds remain neutral, and there are no significant trading trends.
In Q4 2025, TransMedics reported revenue of $160.8M, up 32.18% YoY. Net income increased dramatically by 1436.87% YoY to $105.38M, and EPS rose 1252.63% YoY to 2.57. However, gross margin dropped slightly to 58.11%, down -1.86% YoY.
Analysts have been generally positive on TMDX, with multiple firms raising price targets significantly. The highest target is $175 (Oppenheimer), and the lowest is $130 (Stifel). Most analysts maintain Buy or Outperform ratings, citing strong financial performance, good guidance, and growth opportunities in clinical trials and European expansion.
